- English
- Search
At the 2024 CMAC Conference, Glodom unveiled its AI-powered language solutions for the pharmaceutical sector, emphasizing ISO 13485 compliance and seamless multilingual support. The event highlighted Glodom’s role in streamlining global R&D processes through intelligent translation and risk-managed compliance tools.
Glodom, an AI - powered language services provider, will showcase "Language + Data + AI" solutions at the China (Suzhou) Innovative Drug Medical Conference (Mar 18–20, 2025). As the official interpreter partner, it highlights AI - driven translation, multilingual localization, and regulatory tools for global pharma R&D. Visit Booth B28 for ICH - compliant databases, ISO workflows, and API integrations accelerating clinical trials and cross - border submissions.
Game localization is crucial for global gaming success, adapting content to cultural and emotional nuances of target markets. It involves planning, cultural adaptation, and technical implementation to resonate with players worldwide. Despite challenges like cultural differences and language complexity, emerging markets and AI innovations offer new opportunities. Companies like Glodom specialize in delivering high-quality localization services for game developers.
Glodom's 2024 Annual Meeting, themed "The Golden Snake Soars, and Wisdom Usher in a New Journey", was successfully held on January 18, 2025. With branches connected online, employees shared a wonderful time. It featured speeches, video reviews, performances, lucky draws, and award - giving sessions, followed by offline activities and a dinner, strengthening the company's cohesion and looking forward to the future development.
On December 26th, 2024, the "2025 Overall Pharmaceutical CMC Research Strategy National Tour Salon - API Overseas Expansion Strategy Series" event in Nanjing concluded successfully. Hosted by MilestonePharma and co-organized by Glodom Technology Co., Ltd., it combined offline and online formats, attracting industry experts and enterprises. They discussed CMC strategies, API overseas expansion, and explored new paths for the Chinese pharmaceutical industry.
